Smart insulin dosage software based on trend arrows: an effective method for controlling hyperglycemia in hospitalized diabetic patients in non-endocrine departments (a randomized controlled trial)
Authors:
Open Access
- 16 February 2026
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 86
Abstract
Purpose Artificial intelligence and real-time continuous glucose monitoring (rtCGM) are important inventions in the history of diabetes. The aim of this study was to compare the effectiveness of two methods of glycemic control (smart insulin dosage software and traditional physician’s experience). Methods 86 patients with type 2 diabetes (T2DM) who received multiple daily insulin injections were randomized 1:1 into the smart insulin group (App group) and the traditional physician group (Control group). The former calculates the insulin doses based on an application (which is equipped with trend arrows that reflect the magnitude and direction of glucose changes), while the latter calculates the insulin doses based on physician’s experience. During the study, all participants underwent rtCGM and capillary blood glucose (CBG) testing. The study duration was 5 to 7 days. We compared glucose profile of patients in both group after the intervention. Results Patients in the App group had lower mean CBG (mmol/L) before dinner (10.07 (8.70, 11.60) vs 11.42 (9.89, 14.86), P = 0.006) and at bedtime (9.93 (8.83, 11.33) vs 10.71 (9.62, 12.72), P = 0.039) compared to the control group. The results of rtCGM showed that patients in the App group had lower mean glucose (mmol/L) (9.01(8.04, 9.70) vs10.45 (8.78, 12.27), P = 0.003), higher glucose management index (7.81% (7.09%, 8.59%) vs 7.19%(6.77%, 7.49%), P = 0.003), higher time in range (64.0% (51.0%, 73.0%) vs 47.0% (29.5%, 67.0%), P = 0.001) and less time above of range (35.0% (23.0%, 47.0%) vs 52.0% (29.5.0%, 70.0%), P = 0.003). No significant difference was observed in time below of range (1.0% (0%, 2.0) % vs 0% (0%, 2.5%), P = 0.469). There was no difference in the incidence of hypoglycemia between the two groups of patients (14.0% vs 20.9%, P = 0.394). Conclusion Among T2DM receiving insulin treatment, the smart insulin dosage software with trend arrows has more advantage on controlling hyperglycemia than the physician’s experience. Further research with larger samples and longer durations is needed to support our findings. The clinical trial registration number was NCT05389839.Keywords
All Related Versions
Funding Information
- the Shanghai Public Health Clinical Center (KY-GW-2023-13)
- the Shanghai Municipality Health Commission (202140085)
This publication has 27 references indexed in Scilit:
- Use of smartphone application versus written titration charts for basal insulin titration in adults with type 2 diabetes and suboptimal glycaemic control (My Dose Coach): multicentre, open-label, parallel, randomised controlled trialThe Lancet Regional Health - Europe, 2023
- Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021The Lancet, 2023
- Correlation Between Time in Range and HbA1c in People with Type 2 Diabetes on Basal Insulin: Post Hoc Analysis of the SWITCH PRO StudyDiabetes Therapy, 2023
- Flash glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: a 26 week randomised, controlled, multicentre trialDiabetologia, 2021
- Standards of medical care for type 2 diabetes in China 2019Diabetes/Metabolism Research and Reviews, 2019
- Prevalence of diabetes in liver cirrhosis: A systematic review and meta‐analysisDiabetes/Metabolism Research and Reviews, 2019
- Continuous Glucose Monitoring and Insulin Informed Advisory System with Automated Titration and Dosing of Insulin Reduces Glucose Variability in Type 1 Diabetes MellitusDiabetes Technology & Therapeutics, 2018
- Evaluation of a Novel Continuous Glucose Monitoring-Based Method for Mealtime Insulin Dosing—the iBolus —in Subjects with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Therapy: A Randomized Controlled TrialDiabetes Technology & Therapeutics, 2012
- Management of Insulin Therapy in Urban Diabetes Patients Is Facilitated by Use of an Intelligent Dosing SystemDiabetes Technology & Therapeutics, 2004
- A Bolus Calculator Is an Effective Means of Controlling Postprandial Glycemia in Patients on Insulin Pump TherapyDiabetes Technology & Therapeutics, 2003